Reata Pharmaceuticals, Inc.

171 articles about Reata Pharmaceuticals, Inc.

• 

  Turning to Patients to Help Drive Rare Disease Drug Development

  2/26/2024

  Patient advocacy groups aided in the development of the very first marketed drugs for certain rare diseases, including progeria and Friedreich’s ataxia.
• 

  10 Multibillion-Dollar M&As That Closed Since July 2023

  2/21/2024

  After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.

• BioNTX Celebrates Resilience and Innovation in North Texas Biosciences Ecosystem

  12/15/2023

  BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata Pharmaceuticals over their 20-year journey to success.

• 

  Biogen Lays Off 113 Reata Employees Weeks After Completing $7B Acquisition

  10/12/2023

  The layoffs, set to take effect in late November, will impact about a third of Reata’s headcount. The workforce reduction comes just weeks after Biogen completed its $7.3 billion Reata buy.

• Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

  9/21/2023

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”) announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company’s previously announced acquisition (the “Merger”) by Biogen Inc., a Delaware corporation (“Biogen”).

• Biogen to Acquire Reata Pharmaceuticals

  7/28/2023

  Biogen Inc. (Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.

• 

  Biogen Boosts Neuro Pipeline with $7.3B Reata Buy Amid Layoffs

  7/28/2023

  Following a sweeping cost-cutting plan announced earlier this week, including an 11% workforce reduction, Biogen is acquiring Reata Pharmaceuticals to bolster its neurological and rare disease pipeline.

• Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia

  6/28/2023

  Reata Pharmaceuticals, Inc. announced that the United States Food and Drug Administration has approved the Prior Approval Supplement to update the drug substance specification for SKYCLARYS®, the first and only FDA approved drug for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.

• Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement

  6/16/2023

  Reata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration accepted for filing the Prior Approval Supplement to update the drug substance specification for SKYCLARYS®.

• Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

  6/13/2023

  Reata Pharmaceuticals, Inc., a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer.

• Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference

  6/6/2023

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”) announced that management will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 12 – 15, 2023, in Dana Point, California.

• Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs

  5/10/2023

  Reata Pharmaceuticals, Inc. announced financial results for the first quarter of 2023 and provided an update on the Company’s business operations and clinical development programs.

• Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023

  5/2/2023

  Reata Pharmaceuticals, Inc. announced that it will report financial results for the first quarter ended March 31, 2023, and provide an update on the Company’s business operations and clinical development programs on May 10, 2023, before the U.S. financial markets open.

• Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference

  3/6/2023

  Reata Pharmaceuticals, Inc. announced that management will participate in the Barclays Global Healthcare Conference held next week, March 14-16, in Miami, Florida.

• 

  FDA Approves First Therapy for Friedreich's Ataxia (Updated)

  3/1/2023

  The FDA greenlit Reata Pharmaceuticals' omaveloxolone (Skyclarys) as the first and only treatment for Friedreich’s ataxia, a rare, life-limiting neuromuscular disorder.

• Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia

  2/28/2023

  Reata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.

• 

  Reata Stock Reels as Dunn Departs on Eve of Friedreich’s Ataxia Decision

  2/27/2023

  There are currently no disease-modifying treatments for Friedreich’s ataxia. That could change when the FDA makes a decision about Reata Pharmaceuticals’ omaveloxolone on Feb. 28.
• 

  FDA Action Alert: Cytokinetics, Reata, Regeneron, Pfizer and GSK

  2/27/2023

  The FDA is expected to cap off February with a trio of verdicts, including one for a heart failure treatment and another potential first approval for a rare, neurodegenerative disease.

• Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference

  11/10/2022

  Reata Pharmaceuticals, Inc today announced that management will participate in the Guggenheim 2022 Immunology & Neurology Conference on November 14 – 15, 2022 in New York, NY, and will participate in the Stifel 2022 Healthcare Conference on November 15 – 16, 2022 in New York, NY.

• Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

  11/8/2022

  Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter of 2022 and provided an update on the Company’s business operations and clinical development programs.